From the Research
Castration, or hormonal therapy for prostate cancer, is not directly associated with causing urinary retention, according to the most recent and highest quality study available 1.
Key Points to Consider
- The primary concern with prostate cancer and urinary retention is the physical obstruction caused by the tumor itself, rather than the treatment methods like castration or hormonal therapy.
- Studies have shown that 5-alpha reductase inhibitors, which are used in the treatment of benign prostatic hyperplasia and can reduce prostate size, also reduce the risk of urinary retention 1.
- Alpha-blockers, such as tamsulosin, are effective in managing lower urinary tract symptoms and may have a prophylactic role in reducing the incidence of acute urinary retention in patients undergoing external beam radiotherapy for prostate cancer 2.
- The management of urinary retention in the context of prostate cancer involves addressing both the cancer and the urinary symptoms, with options including catheterization, alpha-blockers, 5-alpha reductase inhibitors, and specific treatments for the cancer itself.
Evidence-Based Recommendations
- For patients with prostate cancer experiencing urinary retention, prompt medical attention is crucial to prevent complications such as urinary tract infections, bladder damage, or kidney problems.
- The use of alpha-blockers and 5-alpha reductase inhibitors can be beneficial in managing urinary symptoms and reducing the risk of urinary retention, as supported by studies 1, 2.
- The choice of treatment should be based on the individual patient's condition, including the stage and aggressiveness of the cancer, and should involve a comprehensive approach addressing both the cancer and the urinary symptoms.